About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Drd2
dopamine receptor D2
MGI:94924
147 phenotypes from 11 alleles in 23 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Drd2m1Anu/Drd2m1Anu
C57BL/NCrlAnu-Drd2m1Anu/Anu 		no abnormal phenotype detected J:104190
Drd2tm1.1Mmsh/Drd2tm1.1Mmsh
Gng7tm1(cre)Mmsh/?
involves: C57BL/6N 		normal behavior/neurological phenotype J:210178
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
B6.Cg-Drd2tm1.1Mrub Slc6a3tm1.1(cre)Bkmn 		abnormal inhibitory postsynaptic currents J:176167
abnormal operant conditioning behavior J:176167
abnormal single cell response J:176167
abnormal synaptic dopamine release J:176167
decreased physiological sensitivity to xenobiotic J:176167
enhanced behavioral response to cocaine J:176167
hyperactivity J:176167
increased physiological sensitivity to xenobiotic J:176167
induced hyperactivity J:176167
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Tg(Nes-cre)1Kln/?
involves: 129S4/SvJae * C57BL/6 * SJL 		abnormal hormone level J:194227
abnormal social/conspecific interaction behavior J:194227
normal behavior/neurological phenotype J:194227
decreased circulating insulin-like growth factor I level J:194227
decreased growth hormone level J:194227
decreased physiological sensitivity to xenobiotic J:194227
decreased somatotroph cell number J:194227
decreased urine major urinary protein level J:194227
normal homeostasis/metabolism phenotype J:194227
postnatal growth retardation J:194227
slow postnatal weight gain J:194227
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Tg(Prl-cre)1Mrub/?
involves: 129S4/SvJae * C57BL/6 * CBA 		decreased physiological sensitivity to xenobiotic J:194227
normal growth/size/body region phenotype J:194227
increased circulating prolactin level J:194227
Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * C57BL/6 		abnormal behavior J:96229
catalepsy J:29045
decreased locomotor activity J:29045, J:96229
decreased vertical activity J:29045
Drd2tm1Ebo/Drd2tm1Ebo
B6.129S2-Drd2tm1Ebo 		increased susceptibility to neuronal excitotoxicity J:65767
Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6 		abnormal adrenal gland zona fasciculata morphology J:110599
abnormal adrenal gland zona reticularis morphology J:110599
abnormal behavior J:96229
abnormal estrous cycle J:41857
abnormal estrus J:41857
abnormal gait J:29045
abnormal melanotroph morphology J:110599
abnormal neuron physiology J:65767
abnormal pituitary gland physiology J:110599
adenohypophysis hyperplasia J:41857
adrenal cortical hyperplasia J:110599
akinesia J:29045
normal behavior/neurological phenotype J:111282
bradykinesia J:29045
catalepsy J:29045
decreased body temperature J:29045
decreased body weight J:29045
decreased circulating estrogen level J:41857
decreased circulating growth hormone level J:41857
decreased fluid intake J:29045
decreased food intake J:29045
decreased lactotroph cell size J:41857
decreased locomotor activity J:29045, J:96229
decreased somatotroph cell number J:41857
decreased vertical activity J:29045, J:96229
enlarged adrenocortical cells J:110599
enlarged pituitary gland J:41857
hyperpigmentation J:110599
hypersecretion of corticosterone J:110599
impaired conditioned place preference behavior J:111282
impaired coordination J:29045
increased circulating adrenocorticotropin level J:110599
increased circulating corticosterone level J:110599
increased circulating pituitary hormone level J:110599
increased circulating prolactin level J:41857
increased lactotroph cell number J:41857
increased pituitary adenoma incidence J:41857
increased susceptibility to neuronal excitotoxicity J:65767
increased susceptibility to pharmacologically induced seizures J:65767
increased thyrotroph cell number J:41857
limp posture J:29045
pituitary gland hyperplasia J:41857
pituitary intermediate lobe hyperplasia J:41857, J:110599
prolonged diestrus J:41857
reduced female fertility J:41857
reduced fertility J:29045
small ovary J:29045
small testis J:29045
Drd2tm1Low/Drd2+
129S/Sv-Drd2tm1Low 		abnormal locomotor behavior J:47001
Drd2tm1Low/Drd2+
B6.129S2-Drd2tm1Low 		abnormal locomotor behavior J:47001
abnormal systemic arterial blood pressure J:103181
ataxia J:50787
normal behavior/neurological phenotype J:50787
decreased locomotor activity J:50787
decreased vertical activity J:47001
impaired behavioral response to alcohol J:50787
increased body weight J:103181
increased mean systemic arterial blood pressure J:103181
increased systemic arterial diastolic blood pressure J:103181
increased systemic arterial systolic blood pressure J:103181
Drd2tm1Low/Drd2+
involves: 129S2/SvPas * C57BL/6J 		abnormal locomotor behavior J:47001
increased physiological sensitivity to xenobiotic J:47001
Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2tm1Low 		abnormal locomotor activation J:47001
abnormal locomotor behavior J:47001
Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2tm1Low 		abnormal brain development J:127071
abnormal CNS synaptic transmission J:127071
abnormal excitatory postsynaptic currents J:127071
abnormal latent inhibition of conditioning behavior J:90593
abnormal locomotor activation J:47001, J:103181
abnormal locomotor behavior J:47001, J:50787
abnormal operant conditioning behavior J:90593
abnormal prepulse inhibition J:55027
abnormal response to novel odor J:110704
abnormal systemic arterial blood pressure J:103181
absent long-term depression J:127071
alcohol aversion J:50787
ataxia J:50787
normal behavior/neurological phenotype J:50787, J:103181, J:110704
decreased alcohol consumption J:50787
decreased body weight J:130701
decreased locomotor activity J:50787
decreased pulmonary ventilation J:130701
decreased startle reflex J:154428
decreased vertical activity J:47001
impaired behavioral response to addictive substance J:55027
impaired behavioral response to alcohol J:50787
impaired coordination J:47001
increased heart rate J:103181
increased mean systemic arterial blood pressure J:103181
increased physiological sensitivity to xenobiotic J:103181
increased pulmonary respiratory rate J:130701
increased pulmonary ventilation J:130701
increased systemic arterial diastolic blood pressure J:103181
increased systemic arterial systolic blood pressure J:103181
increased tidal volume J:130701
increased urine sodium level J:103181
polyuria J:103181
normal taste/olfaction phenotype J:110704
Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2tm1Low/J 		abnormal astrocyte physiology J:194407
abnormal GABAergic neuron morphology J:121219
abnormal neuronal migration J:121219
abnormal vocalization J:134260
astrocytosis J:194407
decreased body length J:106832
decreased body weight J:106832
decreased circulating growth hormone level J:106832
decreased circulating insulin-like growth factor I level J:106832
decreased inguinal fat pad weight J:106832
decreased liver weight J:106832
decreased physiological sensitivity to xenobiotic J:137069
decreased response to stress-induced hyperthermia J:137069
decreased spleen weight J:106832
decreased susceptibility to xenobiotic induced morbidity/mortality J:137069
increased circulating prolactin level J:106832
increased food intake J:106832
increased growth hormone level J:106832
increased interleukin-1 beta secretion J:194407
increased susceptibility to dopaminergic neuron neurotoxicity J:194407
microgliosis J:194407
normal nervous system phenotype J:194407
postnatal growth retardation J:106832
short femur J:106832
Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2tm1Low or (involves: 129S2/SvPas * C57BL/6) 		abnormal adenohypophysis morphology J:41858
abnormal pituitary gland morphology J:41858
adenohypophysis hyperplasia J:41858
adenohypophysis hypertrophy J:41858
adenohypophysis peliosis J:41858
decreased gonadotroph cell number J:41858
decreased physiological sensitivity to xenobiotic J:41858
enlarged pituitary gland J:41858
increased circulating prolactin level J:41858
increased lactotroph cell number J:41858
increased pituitary gland weight J:41858
short uterine horn J:41858
uterus adenomyosis J:41858
uterus cyst J:41858
uterus hyperplasia J:41858
Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6 		abnormal locomotor activation J:102700
Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J 		abnormal locomotor activation J:47001
abnormal locomotor behavior J:47001
decreased physiological sensitivity to xenobiotic J:47001
decreased vertical activity J:47001
Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv 		abnormal single cell response J:97412
Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J 		abnormal circulating hormone level J:97838
abnormal single cell response J:97838
darkened coat color J:97838
enlarged pituitary intermediate lobe J:97838
increased pituitary hormone level J:97838
Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2tm1Schm 		abnormal intestinal absorption J:106280
abnormal intestinal transit time J:106280
abnormal large intestinal transit time J:106280
decreased body weight J:106280
increased defecation amount J:106280
increased fluid intake J:106280
increased food intake J:106280
Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		abnormal dopamine level J:79483
abnormal locomotor behavior J:79483
bradykinesia J:79483
decreased body size J:79483
decreased body weight J:79483
hunched posture J:79483
premature death J:79483
Drd2tm1Smoc/Drd2tm1Smoc
Tg(GFAP-cre)25Mes/0
involves: C57BL/6 * FVB/N 		abnormal astrocyte physiology J:194407
astrocytosis J:194407
normal nervous system phenotype J:194407
Drd2tm1Yyw/Drd2+
B6.129S4-Drd2tm1Yyw 		abnormal behavioral response to xenobiotic J:82829
Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2tm1Yyw 		abnormal behavioral response to xenobiotic J:65770, J:82829
decreased anxiety-related response J:65770
decreased locomotor activity J:65770
decreased vertical activity J:65770
Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6 		bradykinesia J:65770
decreased anxiety-related response J:65770
decreased locomotor activity J:65770
decreased vertical activity J:65770
impaired behavioral response to xenobiotic J:65770
Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6J 		decreased aggression towards male mice J:103562
Drd2tm2Ebo/Drd2tm2Ebo
involves: 129S2/SvPas * C57BL/6 		normal behavior/neurological phenotype J:77277
enhanced behavioral response to xenobiotic J:77277
impaired behavioral response to xenobiotic J:77277
Drd2tm3.1Ebo/Drd2tm3.1Ebo
En1tm2(cre)Wrst/En1+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 		abnormal dopamine level J:185643
abnormal nervous system electrophysiology J:185643
decreased physiological sensitivity to xenobiotic J:185643
enhanced behavioral response to anesthetic J:185643
enhanced behavioral response to cocaine J:185643
enhanced behavioral response to xenobiotic J:185643
hyperactivity J:185643
increased dopamine level J:185643
increased vertical activity J:185643
induced hyperactivity J:185643
Drd2tm3.1Ebo/Drd2tm3.1Ebo
Tg(Drd1a-cre)AGsc/0
involves: 129S2/SvPas * C57BL/6 * FVB/N 		abnormal dopamine level J:185643
abnormal nervous system electrophysiology J:185643
decreased locomotor activity J:185643
decreased physiological sensitivity to xenobiotic J:185643
impaired behavioral response to anesthetic J:185643
impaired behavioral response to cocaine J:185643
impaired coordination J:185643
normal nervous system phenotype J:185643
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
10/29/2024
MGI 6.24 		The Jackson Laboratory